US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

Arvinas Inc (ARVN)

8.59

0.14

(1.66%)

終了 7月8日 5:00AM

8.59

0.00

(0.00%)

取引時間後: 8:00AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company...

Form 8-K - Current report

Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Arvinas Employees Give Back During Company-wide Impact Day

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

bakedog38

bakedog38 1年前

Waiting anxiously for ARVN to get some legs and run!!! ARVN $$$

bakedog38

bakedog38 1年前

Added more today, Good long term hold stock here!

bakedog38

bakedog38 1年前

Good day today. Good gains.

bakedog38

bakedog38 1年前

Bought a position today , hopefully good things to come !

Mr.Mister

Mr.Mister 1年前

Monksdream

Monksdream 2年前

ARVN at a bottom channel

Monksdream

Monksdream 2年前

ARVN new 52=week high

Monksdream

Monksdream 2年前

ARVN new 52 week high

Monksdream

Monksdream 2年前

ARVN new 52 week high

Monksdream

Monksdream 3年前

ARVN new 52 week high

crudeoil24

crudeoil24 6年前

ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”

biocqr

Advantages of PROTACs vs. inhibition...

message_id=152832655

G-lupo

Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25

boo boo

boo boo 7年前

Starting to see a chink in the armor!

G-lupo

Possibly wall at 30.50

G-lupo

I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price

boo boo

boo boo 7年前

The offering:

8-k

boo boo

boo boo 7年前

Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!

boo boo

boo boo 7年前

It doesn't have to be a PR:

#8

G-lupo

Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30

boo boo

boo boo 7年前

https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/

G-lupo

When did they Do a price target announcement? I didn’t see that.

boo boo

boo boo 7年前

If I were in this one (I'm not), I'd be finding the exit on the price target announcement.

G-lupo

Arvn looking good, defintely see $26-27

G-lupo

What you mean IBD?

boo boo

boo boo 7年前

Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...

G-lupo

I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul

boo boo

boo boo 7年前

Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.

G-lupo

What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60

boo boo

boo boo 7年前

Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!

boo boo

boo boo 7年前

boo boo

boo boo 7年前

Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!

PennyStock Alert

PennyStock Alert 7年前

G-lupo

This stock very volatile, no rhyme or reason why it’s been up and down.

morokoy

morokoy 7年前

Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/

Lyxor Asset Management

ERF Wireless (EM)

Military Metals (QB)

51 Talk Online Education

Hungary Central bank bas...

Goodbody Health ()

FCA Bank SpA Irish Branch

Hsbc Bank Usa Na Capped ...

Silver47 Exploration (QX)

Grd Nts Lkd Euro Stoxx B...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。